Drug Profile


Alternative Names: NPI-2358

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator Nereus Pharmaceuticals
  • Developer BeyondSpring Pharmaceuticals; National Cancer Institute (USA); Nereus Pharmaceuticals; University of Washington
  • Class Antineoplastics; Imidazoles; Piperazines; Small molecules
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II/III Neutropenia
  • Phase I Solid tumours
  • Preclinical Glioblastoma
  • Research Brain cancer

Most Recent Events

  • 21 Feb 2017 Efficacy data from a phase II trial in Non-small cell lung cancer released by BeyondSpring Pharmaceuticals
  • 24 Jan 2017 US FDA approves IND application to initiate phase II/III trial of plinabulin in Neutropenia (Prevention, Chemotherapy induced)
  • 19 Dec 2016 Interim efficacy and safety data from a phase II/III trial in Non-small cell lung cancer presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top